Literature DB >> 18589136

Alpha-1-antitrypsin deficiency: outcomes after liver transplantation.

N Kemmer1, T Kaiser, V Zacharias, G W Neff.   

Abstract

Alpha-1-antitrypsin deficiency (AAT) is the most common inherited metabolic disease leading to liver transplantation (LT) in children and adults. The aim of the study was to determine transplantation trends and survival of LT recipients with AAT. Using the UNOS (United Network for Organ Sharing) database, we identified 567 patients who underwent LT and 3 who received lung and LT from 1995 to 2004. AAT accounted for 1.06% of all adult LTs and 3.51% for pediatric LT. The 1-, 3-, and 5-year patient survival was 89%, 85%, and 83%, respectively, for adults versus 92%, 90%, and 90% for pediatric patients (P = .04), and graft survival was 83%, 79%, and 77% for adults versus 84%, 81%, and 78% for pediatric patients (P = .51). By regression analysis, age was the only predictor for patient survival (P = .04). In conclusion, adult and pediatric LT recipients with AAT are predominantly of Caucasian ethnicity and have an excellent post-LT survival.

Entities:  

Mesh:

Year:  2008        PMID: 18589136     DOI: 10.1016/j.transproceed.2008.02.075

Source DB:  PubMed          Journal:  Transplant Proc        ISSN: 0041-1345            Impact factor:   1.066


  12 in total

Review 1.  Current and Future Burden of Chronic Nonmalignant Liver Disease.

Authors:  Prowpanga Udompap; Donghee Kim; W Ray Kim
Journal:  Clin Gastroenterol Hepatol       Date:  2015-08-17       Impact factor: 11.382

2.  Early recognition of alpha-1 antitrypsin deficiency and considerations for liver transplantation.

Authors:  Andreas Tzakis
Journal:  Gastroenterol Hepatol (N Y)       Date:  2013-02

3.  Misdiagnosis of α-1 antitrypsin phenotype in an infant with CMV infection and liver failure.

Authors:  Patricio Arias; John Kerner; Megan Christofferson; William Berquist; K T Park
Journal:  Dig Dis Sci       Date:  2014-08       Impact factor: 3.199

4.  Current and Emerging Treatments for Alpha-1 Antitrypsin Deficiency.

Authors:  David H Perlmutter
Journal:  Gastroenterol Hepatol (N Y)       Date:  2016-07

Review 5.  Diagnosis and management of patients with α1-antitrypsin (A1AT) deficiency.

Authors:  David R Nelson; Jeffrey Teckman; Adrian M Di Bisceglie; David A Brenner
Journal:  Clin Gastroenterol Hepatol       Date:  2011-12-23       Impact factor: 11.382

Review 6.  [Alpha1-antitrypsin deficiency].

Authors:  T Köhnlein; K Rifai
Journal:  Internist (Berl)       Date:  2010-03       Impact factor: 0.743

Review 7.  Why has it been so difficult to prove the efficacy of alpha-1-antitrypsin replacement therapy? Insights from the study of disease pathogenesis.

Authors:  Jennifer A Dickens; David A Lomas
Journal:  Drug Des Devel Ther       Date:  2011-08-17       Impact factor: 4.162

8.  Alpha1-Antitrypsin Deficiency: Transition of Care for the Child With AAT Deficiency into Adulthood.

Authors:  Henry C Lin; Nagraj Kasi; J Antonio Quiros
Journal:  Curr Pediatr Rev       Date:  2019

9.  Gene targeted therapeutics for liver disease in alpha-1 antitrypsin deficiency.

Authors:  Caitriona McLean; Catherine M Greene; Noel G McElvaney
Journal:  Biologics       Date:  2009-07-13

Review 10.  Liver Disease in Alpha-1 Antitrypsin Deficiency: Current Approaches and Future Directions.

Authors:  Ellen L Mitchell; Zahida Khan
Journal:  Curr Pathobiol Rep       Date:  2017-07-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.